Interesting question... but feels like some time related bias or perhaps confounding? Seems implausible that MTX & biologic would be protective for PsO & harmful for PsA @RheumNow #ACR23 Abstr 0498 https://t.co/pSRoLHRTAm

NAFLD a real issue in RA Does DMARD choice matter? National Taiwanese data newly dx RA n=41791 HCQ reduced NAFLD risk: adjHR 0.75 (other RF: obesity, NSAIDs, even low-dose PNL; but not DM, MTX) Can HCQ improve liver health in RA? Authors: ?adiponectin #ACR23 ABST0396 @RheumNow https://t.co/9VMJpImFKs

Join us tonight at 6pm PT/ 9pm ET for our daily #ACR23 recap. https://t.co/0RDwTdzhwS

#ACR23 Abs #0505 found use of IL-17 inhibitors and oral DMARD alone were associated with a decreased likelihood of achieving MDA in PsA. Small sample size, but interesting finding nonetheless. https://t.co/CAZGykwxRT @rheumnow https://t.co/8ptF8aTIFu

Did you know about Tubulointerstitial nephritis uveitis (TINU) syndrome? Usually younger pts; uveitis may not be concurrent with the TIN. Risks: NSAID/abx, infx, genetics. Nice systematic review of this entity (link below). #boardquestion @rheumnow #ACR23 https://t.co/HDqLDHyGM6

FAST trial, MMF vs MTX at the Review Course today Overall a big win for MTX, powered for noninferiority (bc people loved MMF) but looks like MTX won the day w/10% difference in outcomes Take home: MTX FTW per usual @RheumNow #ACR23 #ReviewCourse https://t.co/lY1V6S7X3d

OA and Syncope OA patient on NSAIDs presents with a peptic ulcer and GI Bleed. https://t.co/ezMbqgAB0Q https://t.co/iutdfUAPv2

• ACR QD Clinic - OA and Syncope | RheumNow

I never tire of hearing this story. Biologic DMARDs revolutionized rheumatology & changed millions of lives. How did we get TNFi? Sharp translational insights & courage++ After 4w, RA gone, up/down stairs like a miracle. Sir Ravinder 'Tiny' Maini #ACR23 Global Summit @RheumNow https://t.co/Je1cz3cWG5